Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

Core Insights - Cytokinetics has launched the "On Track with HCM" campaign to support the hypertrophic cardiomyopathy (HCM) community, featuring Sydney McLaughlin-Levrone and her father, Willie McLaughlin, who has lived with HCM for over two decades before receiving a heart transplant [1][2]. Company Commitment - The campaign is designed in collaboration with the HCM patient advocacy community to assist patients in managing the symptoms of HCM in their daily lives [2][4]. - Cytokinetics aims to address both clinical care and the human experience of living with HCM, empowering patients and their families to lead healthier lives [4]. HCM Overview - HCM is the most common inherited heart disease, affecting approximately 1 in every 350 people in the U.S., with many remaining undiagnosed [3][7]. - The disease can lead to serious complications such as atrial fibrillation, heart failure, and sudden cardiac arrest [3][6]. Educational Resources - The "On Track with HCM" program includes a website and eight original videos that share personal experiences and expert insights on managing HCM [2][4]. - The content covers various aspects of living with HCM, including fitness, nutrition, and the mind-body connection [5]. Cytokinetics' Product Pipeline - Cytokinetics is advancing its pipeline of potential new medicines for cardiac muscle dysfunction, including MYQORZO™ (aficamten), which is approved for treating symptomatic obstructive HCM [8]. - The company is also developing other investigational treatments for heart failure and continues research in muscle biology [8].